Date: 2017-02-08
Type of information: Private placement
Company: Coherus Biosciences (USA - CA)
Investors:
Amount:
Funding type: private placement
Planned used: Coherus intends to use the net proceeds from this offering for building the sales and marketing infrastructure for CHS-1701, inventory build, manufacturing and related activities to support the potential launch of CHS-1701, ongoing manufacturing and clinical trial activities for CHS-0214 and CHS-1420, and any remaining proceeds for working capital and other general corporate purposes.
Others: * On February 8, 2017, Coherus BioSciences announced the pricing of its underwritten public offering of 5,154,640 shares of its common stock at a price to the public of $24.25 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 773,196 shares of its common stock at the public offering price, less the underwriting discount, solely to cover over-allotments. The offering is expected to close on or about February 13, 2017, subject to satisfaction of customary closing conditions. * On February 7, 2017, Coherus BioSciences announced it has commenced an underwritten public offering of $125,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of its common stock at the public offering price, less the underwriting discount, solely to cover over-allotments. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan and Citigroup will act as joint book-running managers for the offering. Cowen and Company and BMO Capital Markets will act as lead managers for the offering.
Therapeutic area:
